Strides to market molnupiravir under the brand name Stripiravir
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
The company expects revenue growth of 10-15 per cent in the US
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
Subscribe To Our Newsletter & Stay Updated